USA flag logo/image

An Official Website of the United States Government

Chemosensitivity Tumor Assay & Interphase Cytogenetics

Award Information

Department of Health and Human Services
Award ID:
Program Year/Program:
1993 / SBIR
Agency Tracking Number:
Solicitation Year:
Solicitation Topic Code:
Solicitation Number:
Small Business Information
Oncyte, Inc.
8052 EL RIO Houston, TX 77054
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Phase 1
Fiscal Year: 1993
Title: Chemosensitivity Tumor Assay & Interphase Cytogenetics
Agency: HHS
Contract: N/A
Award Amount: $48,260.00


The objective is to develop a new method for in vitro chemosensitivity and chemoresistance testing of cancer. Phase I will be concerned with an in vitro cell culture system to develop the method. The method will be based upon the use of short-term culture of extirpated tumor cells; this system will monitor the effects of chemotherapeutic drugs on cell proliferation by means of the immunofluorescent detection of bromodeoxyuridine as a measure of DNA synthesis. In order to discriminate tumor cells from the normal diploid stromal cells in the culture, the karyotype of the interphase tumor cells will be will be predetermined by in situ fluorescence hybridation (FISH) prior to BrdUrd pulsing of the cultures, and FISH then performed on the BrdUrd-labeled cells. The dual fluorescence image analysis of IdUrd incorporation and selected FISH probes will distinguish the tumor cells from non-tumor cells in the culture. Corroboration of the identity of tumor cells will be made by a cytopathologist. The method combines the assessment of drug sensitivity of the tumor with the prognostic power of karyotyping.

Principal Investigator:

Howard G. Gratzner

Business Contact:

Small Business Information at Submission:

Oncyte, Inc.
2601 Bellefontaine, Suite C201 Houston, TX 77025

Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No